Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
Biotech
Reviva’s drug reduces symptoms in year-long schizophrenia study
Reviva was testing brilaroxazine, an antipsychotic and dopamine-serotonin system modulator, in the open-label extension of the ongoing RECOVER study.
James Waldron
Dec 16, 2024 10:29am
Eisai pays $46M for Japan rights to Newron's schizophrenia med
Dec 13, 2024 8:37am
AbbVie's $9B schizophrenia prospect flunks phase 2 trials
Nov 11, 2024 10:06am
Teva brings biotech ethos to drug development, exec says
Oct 15, 2024 4:33pm
Neurocrine's bid to save schizophrenia prospect fails
Sep 13, 2024 7:30am
Newron schizophrenia add-on improves positive, negative symptoms
Apr 30, 2024 9:13am
